Download PDF

1. Company Snapshot

1.a. Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors.


In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants.Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.


Revolution Medicines, Inc.was incorporated in 2014 and is headquartered in Redwood City, California.

Show Full description

1.b. Last Insights on RVMD

The recent performance of Revolution Medicines, Inc. has been driven by several positive factors. The company's advanced RAS [ON] inhibitor programs and robust clinical progress, particularly with Daraxonrasib, have garnered significant attention and interest from major pharmaceutical companies. The phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Additionally, the company's presence at the 44th Annual J.P. Morgan Healthcare Conference has further solidified its position in the industry. The conference provided a platform for Revolution Medicines to showcase its pipeline and attract potential investors. Furthermore, the company's acquisition prospects continue to circle, with rumored bids from major pharmaceutical companies, including AbbVie, underscoring its strategic value and enhancing upside optionality. The recent interest from AbbVie, although later denied, has contributed to the company's positive momentum. The company's financials have also been bolstered by the increased interest from investors, with several hedge funds and institutional investors, such as AXQ Capital LP and American Century Companies Inc., taking positions in the company. The company's CFO, Jack Anders, has also been actively buying shares, demonstrating his confidence in the company's prospects. Overall, the combination of the company's advanced pipeline, robust clinical progress, and acquisition prospects has created a positive environment for Revolution Medicines, Inc.

1.c. Company Highlights

2. Revolution Medicines' 2025 Earnings: A Year of Significant Progress

Revolution Medicines reported a net loss of $364.9 million for Q4 2025, with an EPS of -$1.86, missing estimates of -$1.56. The company's R&D expenses were $294.9 million, up from $188.1 million in Q4 2024, primarily due to increased clinical trial and manufacturing expenses. The cash and investments stood at $2.03 billion as of Q4 2025, with an additional $1.75 billion in committed capital from its partnership with Royalty Pharma.

Publication Date: Mar -01

📋 Highlights
  • Pipeline Expansion:: Revolution Medicines advanced its RAS(ON) inhibitor portfolio with 8 ongoing/planned Phase III trials, including daraxonrasib, elironrasib, zoldonrasib, and RMC-5127.
  • Pancreatic Cancer Progress:: Daraxonrasib's RASolute 302 trial enrolled globally, with a 2026 readout expected, alongside new trials (303, 304) targeting first-line and adjuvant settings.
  • Financial Strength:: $2.03 billion in cash (Q4 2025) and $1.75 billion in committed capital from Royalty Pharma, despite a $364.9M net loss in Q4 2025.
  • NSCLC & CRC Strategy:: Combining RAS(ON) inhibitors with pembrolizumab, chemotherapy, and ivoscimab (PD-1/VEGF inhibitor) in NSCLC, and exploring synergistic combos for complex colorectal cancer.
  • Commercial Readiness:: Preparing for potential commercialization post-RASolute 302 data, with leadership teams in place and FDA discussions aimed at expediting reviews via PRV.

Pipeline Advancements

The company made significant progress in its RAS(ON) inhibitor pipeline, with daraxonrasib being evaluated in three randomized registrational studies in pancreatic cancer, including RASolute 302, with global enrollment complete and a readout expected in the first half of 2026. In non-small cell lung cancer (NSCLC), daraxonrasib, zoldonrasib, and elironrasib have shown encouraging safety, tolerability, and antitumor activity. The company plans to initiate a first-line registrational trial of zoldonrasib in combination with standard of care.

Financial Outlook

For 2026, the company expects GAAP operating expenses to be between $1.6 billion and $1.7 billion, including estimated noncash stock-based compensation expense of $180-200 million. Analysts estimate next year's revenue growth at 552.7%. The company's current valuation metrics, including a P/E Ratio of -17.15 and an EV/EBITDA of -17.17, indicate a high level of expectation for future growth.

Business Development and Partnerships

The company remains open to opportunities that can enhance its RAS portfolio, particularly in colorectal cancer (CRC). Revolution Medicines is focused on developing combination therapies involving its RAS(ON) inhibitors, which is the standard of care. The company's plan is to figure out which combinations can make the biggest impact on CRC and prosecute those to registration. As per the staff, "the company has a robust process for evaluating other people's assets and receives a lot of inbound proposals."

Commercialization Readiness

The company is pleased with its launch readiness, with leadership teams in place across commercialization and cross-functional field-based leaders. If the first interim analysis is positive, the company can move forward with commercialization preparations. The company does not plan to hold back on using its Rare Pediatric Disease Priority Review Voucher (PRV) for second-line pancreatic ductal adenocarcinoma (PDAC) when the RASolute 302 data are available.

3. NewsRoom

Card image cap

Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar -03

Source: seekingalpha.com

Card image cap

RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View

Feb -26

Source: zacks.com

Card image cap

Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb -25

Source: globenewswire.com

Card image cap

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb -24

Source: globenewswire.com

Card image cap

20,000 Shares in Revolution Medicines, Inc. $RVMD Purchased by Raiffeisen Bank International AG

Feb -23

Source: defenseworld.net

Card image cap

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb -18

Source: globenewswire.com

Card image cap

Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

Feb -16

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Novel Targeted Therapies

Expected Growth: 10.43%

Revolution Medicines' novel targeted therapies drive 10.43% growth, fueled by increasing adoption in cancer treatment, advancements in precision medicine, and a strong pipeline of innovative candidates. Additionally, strategic partnerships, expanding research and development efforts, and a growing demand for personalized therapies contribute to the company's rapid expansion.

7. Detailed Products

RMC-4630

RMC-4630 is a small molecule inhibitor of SHP2, a key node in multiple signaling pathways, including RAS and PI3K/AKT, that are commonly altered in cancer.

RMC-5552

RMC-5552 is a potent and selective inhibitor of mTORC1, a key regulator of cell growth and metabolism.

RMC-6236

RMC-6236 is a small molecule inhibitor of KRAS(G12C), a common oncogenic mutation in non-small cell lung cancer and other solid tumors.

RMC-6291

RMC-6291 is a small molecule inhibitor of mTORC1/2, a key regulator of cell growth and metabolism.

RMC-4620

RMC-4620 is a small molecule inhibitor of SHP2, a key node in multiple signaling pathways, including RAS and PI3K/AKT, that are commonly altered in cancer.

8. Revolution Medicines, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Revolution Medicines, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and genetic diseases.

Bargaining Power Of Customers

Revolution Medicines, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

Revolution Medicines, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Revolution Medicines, Inc. has a high threat of new entrants due to the growing demand for cancer and genetic disease treatments and the presence of venture capital funding for biotech startups.

Intensity Of Rivalry

Revolution Medicines, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.59%
Debt Cost 3.95%
Equity Weight 95.41%
Equity Cost 11.20%
WACC 10.87%
Leverage 4.82%

11. Quality Control: Revolution Medicines, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Revolution Medicines

A-Score: 4.3/10

Value: 6.2

Growth: 1.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Janux Therapeutics

A-Score: 3.3/10

Value: 7.8

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Iovance Bio

A-Score: 3.1/10

Value: 7.9

Growth: 5.7

Quality: 4.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

100.49$

Current Price

100.49$

Potential

-0.00%

Expected Cash-Flows